Valuation: Cytosorbents Corporation

Market Cap 25.13M 21.71M 20.4M 18.55M 34.87M 2.4B 35.45M 239M 93.44M 1.2B 94.35M 92.31M 4B P/E 2026 *
-1.82x
P/E 2027 * -
Enterprise Value 25.13M 21.71M 20.4M 18.55M 34.87M 2.4B 35.45M 239M 93.44M 1.2B 94.35M 92.31M 4B EV / Sales 2026 *
0.63x
EV / Sales 2027 * 0.53x
Free-Float
84.28%
Yield 2026 *
-
Yield 2027 * -
1 day+10.38%
1 week+11.08%
Current month+10.81%
1 month+8.26%
3 months-19.63%
6 months-37.65%
Current year-37.44%
1 week 0.36
Extreme 0.36
0.4
1 month 0.35
Extreme 0.35
0.4
Current year 0.35
Extreme 0.35
0.84
1 year 0.35
Extreme 0.35
1.19
3 years 0.35
Extreme 0.35
2.88
5 years 0.35
Extreme 0.35
9.8
10 years 0.35
Extreme 0.35
14.95
Manager TitleAgeSince
Chief Executive Officer 55 2008-07-23
Director of Finance/CFO 62 2024-08-13
President 68 2020-04-27
Director TitleAgeSince
Director/Board Member 77 2011-07-24
Director/Board Member 55 2008-12-31
Director/Board Member 65 2014-11-12
Date Insider Type Main position Quantity % Market Cap.
11/18/25 Free

Chief Executive Officer

100,000 0.1593%
8/8/25 Free

Chief Financial Officer

161,500 0.2579%
8/8/25 Free

Chief Executive Officer

242,000 0.3865%
Change 5-day change 1-year change 3-year change Capi.($)
+10.38%+11.08%-65.53%-85.13% 25.13M
-1.28%-0.96%+20.30%+11.24% 218B
-0.71%-1.13%-4.02%-19.91% 142B
-1.68%+4.14%-17.85%+31.80% 139B
+0.27%+5.11%-49.76%+0.72% 75.11B
-1.04%+2.10%+17.05%+16.26% 52.8B
-0.43%-0.26%-17.28%-15.23% 50.66B
-0.51%+1.75%+24.61%+22.39% 41.95B
-0.32%+1.31%+41.37%+49.96% 40.49B
-0.14%+2.68%+0.40%+4.27% 33.28B
Average +0.45%+2.56%-5.07%+1.64% 79.35B
Weighted average by Cap. -0.89%+1.12%+0.46%+9.18%

Financials

2026 *2027 *
Net sales 39.61M 34.21M 32.15M 29.24M 54.97M 3.79B 55.88M 377M 147M 1.9B 149M 146M 6.3B 47.12M 40.7M 38.25M 34.78M 65.39M 4.51B 66.47M 448M 175M 2.26B 177M 173M 7.5B
Net income -13.95M -12.05M -11.32M -10.3M -19.36M -1.33B -19.68M -133M -51.87M -668M -52.37M -51.23M -2.22B -130K -112K -106K -95.96K -180K -12.43M -183K -1.24M -483K -6.22M -488K -477K -20.69M
Net Debt - -
Logo Cytosorbents Corporation
CytoSorbents Corporation is engaged in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. The Company’s blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its lead product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses that can lead to massive inflammation, organ failure and patient death. Its products also include ECOS-300CY, VetResQ, DrugSorb-ATR, and PuriFi. DrugSorb-ATR is an investigational device that uses equivalent polymer technology to CytoSorb to address a large unmet need for blood thinner reversal in cardiothoracic surgery. ECOS-300CY is used to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system.
Employees
129
Date Price Change Volume
26-08-14 $0.3999 +10.38% 66,669
26-08-13 $0.3623 -2.08% 41,887
26-08-12 $0.3700 +2.78% 104,864
26-08-11 $0.3600 -0.55% 40,754
26-08-10 $0.3620 +0.56% 74,586
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.3999USD
Average target price
2.875USD
Spread / Average Target
+618.93%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CTSO Stock